Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety and Tolerability of Oral Clofarabine in Intermediate to High Risk Myelodysplastic Patients

This study has been completed.
Sponsor:
Collaborator:
Genzyme, a Sanofi Company
Information provided by (Responsible Party):
Roswell Park Cancer Institute
ClinicalTrials.gov Identifier:
NCT01003678
First received: October 27, 2009
Last updated: May 8, 2014
Last verified: May 2014

October 27, 2009
May 8, 2014
October 2009
June 2013   (final data collection date for primary outcome measure)
To determine the safety, maximum tolerated dose (MTD) and recommended phase II dose of Clofarabine in patients with myelodysplastic syndrome (MDS). [ Time Frame: Up to 6 months ] [ Designated as safety issue: Yes ]
To determine the safety, maximum tolerated dose (MTD) and recommended phase II dose of Clofarabine in patients with myelodysplastic syndrome (MDS). [ Time Frame: 6.5 years ] [ Designated as safety issue: Yes ]
Complete list of historical versions of study NCT01003678 on ClinicalTrials.gov Archive Site
  • To determine the efficacy of Clofarabine in patients with MDS [ Time Frame: Up to 6 months ] [ Designated as safety issue: No ]
  • To determine the differences in clofarabine triphosphate levels in cells following clofarabine treatment [ Time Frame: Pre, Day 1: Hourly for 6 hours, Pre Day 5:Hourly for 5 hours ] [ Designated as safety issue: No ]
  • Determine the differences in clofarabine plasma levels following clofarabine treatment [ Time Frame: Pre, Day 1: Hourly for 6 hours, Pre Day 5:Hourly for 5 hours ] [ Designated as safety issue: No ]
  • Evaluate the effect of clofarabine on DNA methylation [ Time Frame: Pre and Day 1 ] [ Designated as safety issue: No ]
  • Estimate post-treatment p53R2levels in patients treated at the MTD (in the expanded cohort) [ Time Frame: At 6 months ] [ Designated as safety issue: No ]
To determine the efficacy of Clofarabine in patients with myelodysplastic syndrome (MDS). [ Time Frame: 6.5 years ] [ Designated as safety issue: Yes ]
Not Provided
Not Provided
 
Safety and Tolerability of Oral Clofarabine in Intermediate to High Risk Myelodysplastic Patients
A Phase I Study Evaluating the Safety and Tolerability of Oral Clofarabine in Intermediate to High Risk Myelodysplastic Patients

This is a Phase I trial for patients with intermediate or high risk myelodysplastic syndrome (MDS).

The study agent, clofarabine, is produced by Genzyme Pharmaceuticals.

The specific purpose of the study is to determine the safety, maximum tolerated dose (MTD) and recommended Phase II dose of clofarabine in patients with MDS.

  • We will start at a dose of 1 mg daily.
  • We will treat a group of 3 patients with clofarabine at that dose level.
  • If there are no severe side effects seen at that dose level, then the next group of 3 patients will receive a higher dose.
  • Treatment of groups of 3 patients will continue at higher dose levels until severe side-effects are noted.
  • If more than 1 of the 3 patients experiences a severe side effect, dosing will be stopped at that level.
  • If only one of the three patients experience a severe side effect, then three more patients will be treated, at that dose level and if they too experience severe side effects, then dose escalation will be stopped and the maximum tolerated dose will be determined.
  • 10 more patients will be enrolled at the maximum tolerated dose.
  • There will be up to 5 dose levels tested.
  • We plan to test how much of the drugs are in the patient's blood at different times, and the levels of certain proteins in their blood.
Interventional
Phase 1
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Myelodysplastic Syndrome
Drug: Clofarabine

Dose Escalation Schedule - Level 1: 1 mg daily x 5 days (orally) followed by 23 days off drug.

Levels 2, 3, 4 and 5 are: 3, 5, 10 and 15 mg daily x 5 days followed by 23 days off drug.

Experimental: Level 1
1 mg daily for 5 consecutive days followed by 23 days off drug
Intervention: Drug: Clofarabine
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
4
October 2013
June 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Provide signed written informed consent.
  • Patients with MDS must have IPSS score that falls in the intermediate or high risk disease (intermediate 1 will have to be transfusion dependent).
  • Patients may have received up to two prior therapies for MDS including one hypomethylating agent and/or a biologic agent (biologic agents include GM-CSF or equivalent, danazol or equivalent, Sunitinib, Revlimid, ATG, or a vaccine).
  • Age ≥ 18
  • Have adequate renal and hepatic functions as indicated by the following laboratory values:

    • Serum creatinine ≤ 1 mg/dL; if serum creatinine >l mg/dL, then the estimated glomerular filtration rate (GFR) must be >50 mL/min/1.73 m2 as calculated by the Modification of Diet in Renal Disease equation.
    • Serum bilirubin ≤1.5 mg/dL x upper limit of normal (ULN)
    • Aspartate transaminase (AST)/alanine transaminase (ALT) ≤2.5 x ULN
    • Alkaline phosphatase ≤2.5 x ULN
  • Capable of understanding the investigational nature, potential risks and benefits of the study, and able to provide valid informed consent.
  • Female patients of childbearing potential must have a negative serum pregnancy test within 2 weeks prior to enrollment.
  • Male and female patients must use an effective contraceptive method during the study and for a minimum of 6 months after study treatment.

Exclusion Criteria:

  • Have any other severe concurrent disease, or have a history of serious organ dysfunction or disease involving the heart, kidney, liver, or other organ system that may place the patient at undue risk to undergo treatment.
  • Active CNS disease
  • Patients with a systemic fungal, bacterial, viral, or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment).
  • Pregnant or lactating patients.
  • Any significant concurrent disease, illness, or psychiatric disorder that would compromise patient safety or compliance, interfere with consent, study participation, follow up, or interpretation of study results.
  • Have had any prior treatment with clofarabine
  • Have had a diagnosis of another malignancy, unless the patient has been disease free for at least 3 years following the completion of curative intent therapy, with the following exceptions:

    • Patients with treated non-melanoma skin cancer, in situ carcinoma, or cervical intraepithelial neoplasia, regardless of the disease-free duration, are eligible for this study if definitive treatment for the condition has been completed.
    • Patients with organ-confined prostate cancer with no evidence of recurrent or progressive disease based on prostate-specific antigen (PSA values are also eligible for this study if hormonal therapy has been initiated or a radical prostatectomy has been performed.
  • Have prior positive test for the Human Immunodeficiency Virus (HN).
  • Have prior positive test for the Human Immunodeficiency Virus (HN).
  • Have currently active gastrointestinal disease, or prior surgery that may affect the ability of the patient to absorb oral clofarabine.
  • Patients taking proton pump inhibitors such as omeprazole (Prilosec®), lansoprazole (Prevacid®), or esomeprazole (Nexium®). Those who cannot stop taking these drugs should be switched to H2 blockers such as famotidine (Pepcid®)or ranitidine (Zantac®).
  • Patients taking alternative medicines (such as herbal or botanical) are not permitted.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01003678
I 144208
Yes
Roswell Park Cancer Institute
Roswell Park Cancer Institute
Genzyme, a Sanofi Company
Principal Investigator: Wetzler Meir, MD Roswell Park Cancer Institute
Roswell Park Cancer Institute
May 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP